#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Parkinson's disease Subarachnoid haemorrhage Phaeochromocytoma Acute myeloid leukaemia refractory Congenital hypotransferrinaemia Myxoid liposarcoma Prader-Willi syndrome Anal squamous cell carcinoma Diffuse large B-cell lymphoma recurrent Anti-myelin-associated glycoprotein associated polyneuropathy B-cell small lymphocytic lymphoma Juvenile psoriatic arthritis Aicardi-Goutieres syndrome Meningitis meningococcal Thrombotic microangiopathy More trials…

    Learn about Rare Diseases

    Castleman’s disease – Treatment Cytokine release syndrome – Treatment Angiosarcoma recurrent – Life with Disease Inclusion body myositis Marginal zone lymphoma refractory – Trials in Disease Epidermolysis bullosa – Life with Disease Lymphangioma – Basic Information Paroxysmal nocturnal haemoglobinuria Familial haemophagocytic lymphohistiocytosis – Life with Disease Angiosarcoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Afamitresgene Autoleucel Exl01 Sodium Fluoride (18F) Aztreonam Paracetamol Ph. Eur. Alnus Glutinosa Pollen Anb032 Tucatinib Eprosartan Mesilate Vinblastine Sulfate Izaflortaucipir (18F) Human Fibrinogen Lenalidomide ALN-4324 Sot102 Arbaclofen Cefepime Lu Ag09222 Dazostinag Livmoniplimab More therapies…

    Learn about Your Condition

    Vulvovaginal candidiasis Graves' disease Merycism Mitral valve prolapse Paresis Essential thrombocythaemia Glomerulonephritis chronic Constipation Nasopharyngeal cancer Dengue fever Chronic granulomatous disease Breast angiosarcoma metastatic Extra-osseous Ewing's sarcoma K-ras gene mutation Femoral neck fracture More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Bacs-Kiskun Varmegyei Oktatokorhaz

Bacs-Kiskun Varmegyei Oktatokorhaz

Nyiri Ut 38, Kecskemet, 6000, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Mrna-4157
    • Pembrolizumab
    Belgium Czechia Denmark Estonia Finland France +12

  • Study of Patritumab Deruxtecan for Patients with Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    Investigated Drugs:
    • Patritumab Deruxtecan
    Belgium France Germany Hungary Italy The Netherlands +2

  • Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiac failure
    Investigated Drugs:
    • Balcinrenone
    • Dapagliflozin
    Austria Bulgaria Czechia Finland France Germany +9

  • Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Datopotamab Deruxtecan
    • Infliximab
    • Mycophenolate Mofetil
    Austria Belgium Germany Hungary Italy Poland +1

  • Study on THIO and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • 2-Amino-9-((2R,4R,5R)-4-Hydroxy-5-(Hydroxymethyl) Tetrahydrofuran-2-Yl)-1,4,5,9-Tetrahydro-6H-Purine-6-Thione
    • Cemiplimab
    Bulgaria Hungary Poland Romania

  • Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Favezelimab
    • Olaparib
    • Lenvatinib
    Austria Belgium Czechia Denmark Estonia Finland +15

  • Study on TAK-330 for Reversing Anticoagulation in Patients on Factor Xa Inhibitors Needing Urgent Surgery

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Thrombosis prophylaxis
    Investigated Drugs:
    • Human Coagulation Factor Ii
    • Human Coagulation Factor Ix
    • Human Coagulation Factor Vii
    Austria Belgium Czechia France Germany Greece +5

  • A study of MK-1084 and a drug combination for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations.

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Patritumab Deruxtecan
    • Cetuximab
    • Mk-1084
    Germany Greece Hungary Italy Poland Spain

  • VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

    Recruiting

    3 1 1
    Investigated Drugs:
    • VMX-C001
    Austria Belgium Bulgaria Czechia Estonia France +9

  • A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

    Recruiting

    3 1 1
    Investigated Drugs:
    • Op-1250
    • PALAZESTRANT
    • Letrozole
    Austria Belgium Czechia France Germany Greece +7
Previous Page
1 2 3 4 5 6 … 13
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!